After the third course, the mean PAM-Hb levels increased to 211.7 pmol g−1 Hb for breast cancer patients in the C500 group and 291.6 pmol g−1 Hb for breast cancer patients in the C600 group. This evidence concerns the gene GSTM1 and breast carcinoma.